FDA.reportPublic FDA data

sodium oxybate 6000 MG Granules for Oral Suspension

RxCUI
2636830
RxNorm name
sodium oxybate 6000 MG Granules for Oral Suspension
Display name
sodium oxybate 6000 MG Granules for Oral Suspension
Full name
sodium oxybate 6000 MG Granules for Oral Suspension
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
10e5e40c-52f3-4c73-8a34-2c29c690a934sodium oxybate 6 GM Granules for extended release Oral Suspension [PSN] · sodium oxybate 6000 MG Granules for Oral Suspension [SCD] · sodium oxybate 6 GM (equivalent to 5 GM oxybate) Granules for Oral Suspension [SY]310These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII Initial U.S. Approval: 200220251204